Clinical Trial Update: Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of Interleukin-2 plus Bryostatin-1 in patients with melanoma or kidney cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Melanoma

Drugs mentioned

• Bryostatin-1 (bryostatin-1)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Kidney Cancer, Melanoma (Skin) | Phase 1 | Status: COMPLETED